Enzo Biochem and Agilent agree $9 million settlement
New York | 11 January 2016

Enzo Biochem has reached a $9 million settlement with Agilent Technologies.

Agilent will pay Enzo the sum to settle a dispute alleging the infringement of its patent covering nucleic acids.

Enzo initially filed against Agilent in the US District Court for the District of Delaware, arguing that Agilent infringed its patent by selling certain nucleic acid array products in the US, without its permission.

The settlement is only one of the 11 cases originally brought by Enzo in district court alleging patent infringement. Eight are still pending.

Barry Weiner, president of Enzo, said the company has received more than $65 million in settlements and licensing revenues in the last few years.

Author: Tammy Facey



More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences
IPPRO ARCHIVES
BACK ISSUES ONLINE
COMPANY INFO
ABOUT US

THE TEAM


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization